JP2010505801A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505801A5
JP2010505801A5 JP2009530916A JP2009530916A JP2010505801A5 JP 2010505801 A5 JP2010505801 A5 JP 2010505801A5 JP 2009530916 A JP2009530916 A JP 2009530916A JP 2009530916 A JP2009530916 A JP 2009530916A JP 2010505801 A5 JP2010505801 A5 JP 2010505801A5
Authority
JP
Japan
Prior art keywords
vaccine
serotype
den
vaccine composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009530916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505801A (ja
JP5269796B2 (ja
Filing date
Publication date
Priority claimed from FR0608660A external-priority patent/FR2906724B1/fr
Application filed filed Critical
Publication of JP2010505801A publication Critical patent/JP2010505801A/ja
Publication of JP2010505801A5 publication Critical patent/JP2010505801A5/ja
Application granted granted Critical
Publication of JP5269796B2 publication Critical patent/JP5269796B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009530916A 2006-10-04 2007-10-02 ４種のデング血清型に対する免疫付与の方法 Expired - Fee Related JP5269796B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.
FR0608660 2006-10-04
PCT/FR2007/052054 WO2008047023A2 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (3)

Publication Number Publication Date
JP2010505801A JP2010505801A (ja) 2010-02-25
JP2010505801A5 true JP2010505801A5 (https=) 2010-10-28
JP5269796B2 JP5269796B2 (ja) 2013-08-21

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530916A Expired - Fee Related JP5269796B2 (ja) 2006-10-04 2007-10-02 ４種のデング血清型に対する免疫付与の方法

Country Status (15)

Country Link
US (2) US7718358B2 (https=)
EP (3) EP2526965A1 (https=)
JP (1) JP5269796B2 (https=)
KR (1) KR20090064593A (https=)
CN (2) CN101553251B (https=)
AR (1) AR063057A1 (https=)
AU (1) AU2007311792B2 (https=)
BR (1) BRPI0719849A2 (https=)
CA (1) CA2663885A1 (https=)
FR (1) FR2906724B1 (https=)
IL (2) IL197768A0 (https=)
MX (1) MX2009003417A (https=)
TW (2) TWI406673B (https=)
WO (1) WO2008047023A2 (https=)
ZA (1) ZA200901816B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) * 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
EP2473624B1 (en) 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
SG195115A1 (en) * 2011-06-29 2013-12-30 Immunotope Inc Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
NZ630831A (en) * 2012-06-10 2019-02-22 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
KR20150036593A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
MX381497B (es) 2012-07-24 2025-03-12 Sanofi Pasteur Composiciones vacuna.
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
BR112015031226A2 (pt) 2013-06-21 2017-08-29 Merck Sharp & Dohme Composição de vacina, e, uso da composição de vacina
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3236997B1 (en) 2014-12-22 2024-05-29 Merck Sharp & Dohme LLC Dengue virus vaccine compositions and methods of use thereof
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
EP3382012A4 (en) * 2015-11-27 2019-07-03 KM Biologics Co., Ltd. LIVING VIRUS WITH A BANK OF ATTENUATED TREES OF DENGUEVIRUS AND DENGUE VACCINE THEREFORE AS ANTIGENE
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
MX2022001742A (es) 2019-08-16 2022-04-07 Takeda Vaccines Inc Metodos para prevenir el dengue y la hepatitis a.
EP4110381A1 (en) 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (en) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381B1 (en) 2022-11-18 2026-02-25 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated dengue virus having a nucleotide sequence comprising at least one attenuation locus in a formulation
CN120529951A (zh) 2022-11-29 2025-08-22 武田疫苗股份有限公司 大规模黄病毒疫苗生产和制造
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
HU228705B1 (en) 1997-02-28 2013-05-28 Univ St Louis Chimeric flavivirus vaccines
AU4224499A (en) 1998-05-29 1999-12-13 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
AU4179200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
JP2002540166A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱３型ウイルスワクチン
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
US6537557B1 (en) * 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP3000477A1 (en) 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
DK2290109T3 (da) 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
WO2002102828A2 (en) 2001-06-01 2002-12-27 Acambis, Inc. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
KR101194818B1 (ko) * 2002-01-15 2012-10-25 사노피 파스테르 바이오로직스, 엘엘씨 플라비바이러스 백신
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
DE602004027902D1 (de) 2003-03-24 2010-08-12 Scripps Research Inst Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Similar Documents

Publication Publication Date Title
JP2010505801A5 (https=)
JP2010511022A5 (https=)
MX2009004223A (es) Protocolo de inmunizacion contra los 4 serotipos del dengue.
WO2008047023A3 (fr) Methode d'immunisation contre les 4 serotypes de la dengue
JP2015524421A5 (https=)
JP2007302683A5 (https=)
IL207468A (en) HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
WO2008022196A3 (en) Development of dengue virus vaccine components
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
NO20090141L (no) Stabiliserte, farmasøytiske preparater som omfatter fesoterodin
JP2002540168A5 (https=)
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
MY184428A (en) Compositions and methods for administration of vaccines against dengue virus
WO2006083286A3 (en) Genetically engineered swine influenza virus and uses thereof
FI2313087T4 (fi) Farmaseuttinen annostelumuoto indolinoni-johdannaisen välittömään vapautumiseen
FI3250182T3 (fi) Dispergoituvia koostumuksia
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
JP2010520246A5 (https=)
ATE419006T1 (de) Multivalenter dengue-virus impfstoff
WO2006088481A3 (en) Genetically engineered equine influenza virus and uses thereof
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
MX351380B (es) Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino.
WO2002024897A3 (en) Conditionally replicating viral vectors and their use
JP2009515987A5 (https=)